(NASDAQ: SRZN) Surrozen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.3%.
Surrozen's earnings in 2026 is -$332,130,000.On average, 8 Wall Street analysts forecast SRZN's earnings for 2026 to be -$84,910,054, with the lowest SRZN earnings forecast at -$92,493,449, and the highest SRZN earnings forecast at -$67,383,148. On average, 8 Wall Street analysts forecast SRZN's earnings for 2027 to be -$43,298,932, with the lowest SRZN earnings forecast at -$57,707,619, and the highest SRZN earnings forecast at -$28,755,080.
In 2028, SRZN is forecast to generate -$43,707,956 in earnings, with the lowest earnings forecast at -$60,817,611 and the highest earnings forecast at -$30,853,090.